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This is a retrospective comparison of pregnant women with perinatally acquired HIV-infection (PAH) with a
cohort of pregnant women with behaviorally acquired HIV-infection (BAH). PAH cases (11 women) included all
pregnant adolescents followed at our HIV clinic from January 2000 to January 2009. BAH cases (27 women) were
randomly selected from all deliveries within the study period at the same institution. Demographics, mode of
delivery, CD4  counts, and viral loads (VLs) before, during, and six months postpartum, as well as neonatal
outcomes, were reviewed.
CD4 counts were significantly lower in the PAH group. VLs were statistically higher in the PAH group. VLs
were undetectable at delivery in 60% of the PAH group compared with 88% of the BAH group. No cases of
vertical transmission occurred.
PAH women may be at a higher risk for HIV-related disease progression. This may increase vertical
transmission risks. Further studies and interventions with this growing population are warranted.
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Introduction
Advances in the management of HIV infection have
enabled a growing group of young women with
perinatally acquired HIV-infection (PAH) to enter
their childbearing years. In the USA, approximately
10,000 perinatally infected children are now transi-
tioning into adolescence and young adulthood; many
of them may eventually become parents (Fowler
et al., 2004; Rangel et al., 2006). In terms of sexual
behaviors, PAH adolescents and young adults do not
differ significantly from their uninfected peers
(Zorrilla et al., 2003). In addition, overall reproduc-
tive health in HIV-infected individuals has mirrored
the advances in antiretroviral (ARV) therapy and has
led to an increase in the pregnancy rate (Blair et al.,
2004; Brogly et al., 2007; Ventura et al., 2008).
Similarly, the prevention of mother to child HIV
transmission (MTCT) has improved dramatically
over the last two decades (Fowler et al., 2004;
Mofenson et al., 2006), and clinicians are more
experienced and confident in the management of
pregnant women with HIV infection. Guidelines on
the management of such pregnancies are widely
disseminated and are regularly updated. Currently,
vertical HIV transmission rates in the USA are at 2%
(Cooper et al., 2002). In 2006, strict adherence to New
York State Department of Health guidelines, which
mandate HIV counseling and testing of all pregnant
women, coupled with a robust newborn screening
protocol have further reduced transmission rates to
1.7% (New York State Department of Health,
personal communication 2008).
Young women with PAH represent a growing
population with unique issues related to pregnancy.
The management of pregnancies in adolescents and
young women with PAH is complicated by their
extensive ARV treatment experience, the presence of
multidrug-resistant (MDR) virus, histories of subop-
timal adherence, limited therapeutic options, psycho-
social issues, and others. Healthy teenagers struggle
with a wide array of challenges relating to their
physiological, emotional, and psychosocial develop-
ment. For adolescents with PAH, this already difficult
period is further exacerbated by the stigma of HIV
infection, chronic illness, and inexorable psychosocial
chaos.Pregnancy, oftenunplanned, addsanother level
of complexity and treatment challenges. There are
limited published data specifically addressing preg-
nancies in women with PAH. This retrospective study
reports systematically collected information on this
unique population, and contrasted their outcomes
with a historically well-described group of pregnant
women with behaviorally acquired HIV-infection
(BAH).
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Our setting is an urban municipal medical center in a
high-HIV seroprevalent area. PAH cases included all
perinatally infected HIV adolescents and young
adults followed at our institution for comprehensive
HIV care who had given birth to live infants from
January 2000 to January 2009. If a woman became
pregnant more than once, each pregnancy was
considered as a separate event. This approach was
taken as multiple HIV-specific variables (clinical
illness, viral load, and CD4 parameters), drug avail-
ability and resistance, adherence as well as psychoso-
cial conditions may vary from pregnancy to
pregnancy. An adequate age-matched control group
of women with BAH was not available at our
institution. To highlight the differences and unique
qualities and challenges of the PAH group, we chose
to use a comparison group randomly selected from a
list of all pregnant women with BAH who delivered
live infants during the same period and who had
attended the adult outpatient HIV clinic at our
institution. A ratio of approximately two BAH
pregnancies for every PAH pregnancy was used to
identify contrasting differences between these two
groups.
Data abstracted from the medical records in-
cluded demographics, mode of delivery, CD4 counts,
viral load (VL), and ARV regimens before, during,
and after pregnancy. CD4 counts and VLs were
calculated as an average of all available values one
year before, during the three trimesters of pregnancy,
and six months postpartum. Newborn data included
perinatal history, gestational age, weight at birth, and
HIV-infection status.
In our institution we follow a Family Center Care
Model, whereby weekly multidisciplinary perinatal
meetings (attended by pediatric and adult clinicians,
mental health providers, and case managers) are held
to discuss comprehensive management plans for the
pregnant women. Both PAH and BAH women
received their obstetric care from the same personnel
in the HIV Family Center Care. Supportive services
not provided on site are referred to community-based
organizations with which we have developed close
working relationships.
Statistical analyses
Data distribution was tested by the Anderson 
Darling normality test. Bivariate comparisons of
CD4  T lymphocyte counts and plasma VLs at
different time points were assessed using the Mann 
Whitney U test. Fisher exact test (two tailed) was used
to compare the mode of delivery (cesarean section vs.
vaginal) and VLs (undetectable at 400 copies/mL) at
the time of birth (Minitab; Statistical Software, State
College, PA).
Results
PAHcases included 11 women with15 live births (four
women had two pregnancies each). BAH cases were
represented by 27 women, with 33 live births (six
womenhadtwopregnancieseach).Allofthewomenin
this study were of Hispanic or African-American
descent. As expected from the cohorts’ definition, the
mean ages in the PAH and BAH groups were 20.8
(17.5 24.8) and 30.3 (19.3 36.8) years, respectively.
The women in the PAH group were highly treatment
experienced; during their pregnancies, 10 of 11 (14/15
pregnancies) were prescribed protease inhibitor (PI)-
based combination antiretroviral therapy (cART)
containing three to four drugs. In the BAH group,
the women received cART that was either PI (23)
or non-nucleoside reverse transcriptase inhibitor
(NNRTI) (8) based (Table 1).
All women received MTCT prophylaxis during
labor and delivery, and all newborns were treated
postnatally in accordance with established guidelines
(US Department of Health and Human Services,
2009). Three of the newborns in the PAH group
received a three-drug prophylaxis regimen because of
heightened concerns about vertical transmission of
resistant virus in the setting of persistent maternal
drug-resistant viremia during the peripartum period.
Three women in the PAH group also had chronic
viral hepatitis, one with hepatitis B virus (HBV) and
two with hepatitis C virus (HCV).
Immunologic and virologic parameters were, in
general, worse in the PAH group than in the BAH
group. At all stages of pregnancy, median CD4
counts were consistently and significantly lower in
the PAH group (Table 2 and Figure 1). The median
VL before pregnancy, during the second and third
trimesters of pregnancy, and in the postpartum
period was statistically higher in the PAH group
(Table 2 and Figure 2). Undetectable VLs (B400
copies /mL) at delivery were achieved in 29 of 33
(88%) pregnancies in the BAH group as compared
with 9 of 15 (60%) pregnancies in the PAH group
(p 0.03, Fisher exact test). During the post-partum
period, persistent viral replication occurred more
commonly in the PAH group (Table 2 and Figure 2).
Cesarean section at term was the mode of delivery in
12 of 15 (80%) of the PAH women and 13 of 33 (39%)
women of the BAH group, a statistically significant
difference (p 0.009; Fisher exact test). In terms
of neonatal outcomes, there were four preterm
AIDS Care 1077deliveries, two in the BAH group (34 and 35 weeks
of gestation) and two in the PAH group (32 and 34
weeks of gestation). The mean gestational ages for
the PAH and BAH newborns were 37 and 40
weeks, respectively. The mean birth weight in the
PAH group was 2688 g (1525 3440 g), significantly
lower than 3117 g (1265 3920g) in the BAH group
(p 0.0027, Mann Whitney U test) and not attri-
butable to differences in gestational ages. Impor-
tantly, no maternal to child HIV transmission
occurred in either group. While no cases of vertical
HCV transmission were observed, perinatal HBV
infection occurred in one child despite the admin-
istration of passive and active immunoprophylaxis.
Discussion
Epidemiologic trends predict that the incidence of
pregnancy in women with PAH will rapidly increase
over the next decade (Rangel et al., 2006). Study is
among the initial comprehensive descriptions of
neonatal outcomes and changes in HIV disease
markers in a group of pregnant perinatally infected
women.
As the HIV epidemic enters its third decade,
clinicians continue to gain more experience in the
management of pregnancy and prevention of MTCT
in women with BAH who are naive or minimally
exposed to ARVs (US Department of Health and
Human Services, 2009). However, information on the
management of pregnant women with extensive treat-
ment experience and drug resistance is limited (Arrive
et al., 2007). The PAH cohort presents management
challenges resulting from previous exposure to serial
nonsuppressive regimens and the emergence of MDR-
HIV. To overcome existent resistance, increasingly
complex regimens with potential greater toxicities are
prescribed, which may perpetuate the cycle of non-
adherence and additional viral drug resistance.
Although no MTCT occurred in our cohort, the
implications of poor immunologic and virologic
markers in the PAH pregnant group require thought-
ful prevention strategies to address this expanding
population of pregnant adolescents and young adults.
It is concerning that although the MTCT rates have
fallen dramatically, the prevalence of drug resistance
in the group of vertically infected infants in New
York state increased 58% between 1998 and 2002
Table 1. Demographic, clinical, and laboratory characteristics of women with behaviorally (BAH) and perinatally acquired
HIV (PAH).
Behaviorally acquired HIV
(BAH) N   27 subjects
(n 33 pregnancies)
Perinatally acquired HIV
(PAH) N 11 subjects
(n 15 pregnancies)
Race
Hispanics 6 7 (0.47%)
African Americans 21 (78%) 4
Highly active antiretroviral therapy (HAART) n   33 n   15
Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) 31 15
NNRTI 8 1
PI 23 13
HIV RNA levels (copies/ml at delivery) n 33 n 15
B400 29 (88%) 9 (60%)
400 1000 1 1
1000 B10,000 1 2
 10,000 2 3 (20%)
Birth weight (g) n 31 n 15
1500 2000 2 1
2000 2500 2 1
2500 3000 4 12 (80%)
 3000 23 (66%) 2
Gestational age (weeks) n 31 n 15
39 40 20 (65%) 1
37 38 9 (29%) 12 (80%)
B37 2 2
Mode of delivery n 33 n 15
Cesarean section 13 (39%) 12 (80%)
Normal spontaneous vaginal delivery (NSVD) 20 3
1078 U.K. Phillips et al.(Foster et al., 2006; Karchava et al., 2006). High rates
of suboptimal virologic control close to the time of
delivery led to more planned cesarean sections being
done in the PAH group, and concerns regarding
MDR HIV transmission prompted us to prescribe
aggressive postnatal prophylaxis consisting of PI- or
NNRTI-based cART to three infants born to
mothers in the PAH cohort.
In addition to presenting with more complex
treatment histories and drug resistance patterns, the
women in the PAH cohort have distinct psychosocial
and behavioral risks that set them apart from their
BAH counterparts. These risks can in part be
attributed to the normal developmental stages of
adolescence but are compounded by the high pre-
valence of medical and psychiatric problems in this
group (DeMatteo, Wells, Salter Goldie, & King,
2002; Karatzios et al., 2007). Three key issues
affecting adolescents with PAH today are social
stigma, sexuality, and mental health disorders
(Ezeanolue et al., 2006; Mellins et al., 2006). Stigma
is closely associated with disclosure of their HIV
status to others and concerns about negative con-
sequences in terms of relationships and choices
Table 2. Immunologic (CD4 cells/uL) and virologic (log10 copies/mL) parameters (median values) before, during, and after
pregnancy. The groups were compared using Mann Whitney U test; BAH (n 33 pregnancies) and PAH (n 15
pregnancies).
CD4 absolute VL log10
BAH PAH p-Value BAH PAH p-Value
Before pregnancy 377 144 0.0001 2.6 3.62 0.017
During pregnancy
First trimester 367 128 0.0012 3.44 2.97 0.55
Second trimester 382 123 0.0003 2.35 3.24 0.003
Third trimester 424 158 0.0003 1.7 2.7 0.02
Post partum period
At delivery 422 169 0.0003 1.7 2.39 0.22
Three months 478 197 0.0001 2.39 3.89 0.0006
Six months 510 126 0.0006 2.29 3.93 0.001
Note: Values shown in bold are statistically significant.
Figure 1. Longitudinal immunologic assessment of PAH and BAH groups before, during, and after pregnancy. Median
values of CD4  T lymphocyte counts (cells/uL) are depicted on the Y axis and time in months on the X axis. Diamonds and
squares represent the BAH and PAH groups, respectively.
AIDS Care 1079related to sex and sexual orientation (Mellins et al.,
2002). Studies have shown that approximately
60% of adolescents with PAH manifest evidence of
a DSM IV diagnosis including depression, anxiety,
impulsivity, and posttraumatic stress disorder
(Mellins et al., 2009). These and other factors are
associated with poor adherence and require special
consideration when the teenager becomes pregnant
(Bardeguez et al., 2008).
Adolescent pregnancy in the absence of HIV
infection is recognized as a significant social issue
and is frequently complicated by chronic poverty,
unstable home environments, and other adverse
academic and psychosocial circumstances (Grady &
Bloom, 2004; Miller, 2000). Many pregnant adoles-
cents have inconsistent prenatal care and are at a
higher risk for pregnancy-related complications and
infant morbidities such as premature birth and low
birth weight (Klein & the Committee on Adolescence,
2005;Rees,Lederman,&Kiely,1996).Whilemuchhas
beenwrittenonHIV,pregnancy,andthepreventionof
vertical infection, there is a paucity of literature
addressing HIV infection in pregnant, vertically in-
fected adolescents and young adults. While the mean
age of our PAH group was 20.8 years (range 17 22
years), we did not observe higher birth weights, which
may be attributed, in part, to elective cesarean section
at no later than 37 38 weeks of gestation and to the
overall impact of chronic illness.
Our observation on the impact of pregnancy on
the immunologic status of young women with PAH
merits comment. The PAH cohort exhibited median
CD4 cell counts consistently below 200 cells/uL
throughout pregnancy, which requires prescribing
Pneumocystis jirovecii prophylaxis, further complicat-
ing the cART regimen. A subgroup of these women
experienced robust CD4 count increases in response
to their cART, suggesting that this population still
retains the capacity for at least partial immune
reconstitution. In contrast, the women in the BAH
group had higher median CD4 counts at baseline, less
advanced disease, and more robust increases in CD4
parameters during pregnancy, which persisted into the
postpartum period. Importantly, all the women in the
PAH group experienced sustained loss of virologic
control during the postpartum period, suggesting that
this population returns to its prepregnancy behavioral
patterns, that is, nonstructured lifestyles and chronic
inconsistent medication adherence. In addition, stres-
sors associated with having a new infant and the
abrupt change from their role from care-receiver to
caregiver strains their already compromised coping
skills. These new dynamics raise even higher psycho-
logical barriers that these young women must sur-
mount in order to access and optimize their own
healthcare. Poor postpartum adherence to ART regi-
mens in the PAH group has significant adverse health
consequences resulting in virologic and immunologic
deterioration and more rapid disease progression or
Figure 2. Longitudinal virologic assessment of PAH and BA groups before, during, and after pregnancy. Median values of
log10 HIV RNA copies/mL are depicted on the Y axis and time in months on the X axis. Diamonds and squares represent the
BAH and PAH groups, respectively.
1080 U.K. Phillips et al.death after the birth of their child. Of great concern,
within the PAH cohort, 3 of the 11 (27%) women
died: one each at two, three, and four years post-
partum. The underlying reasons for these deaths are
undoubtedly multifactorial but may be related to
stressors associated with first-time motherhood. Post-
partum depression may have accentuated or triggered
dormant or undiagnosed psychiatric disorders (Bla-
ney et al., 2004; Mellins et al., 2009). The complex
interplay between nonadherence, postpartum depres-
sion, lack of social support, and treatment fatigue
related to the chronic nature of HIV infection
contribute to bad virological and clinical outcomes
in our population.
A limitation of this study is that we were unable to
address the question whether the pregnancies were
planned or not, an area that merits further considera-
tion. Although some investigators have reported that
70%offemaleadolescentsandyoungadultswithPAH
expressed a desire to have children, details of their
motivations and reproductive decision making are not
well understood (Ezeanolue et al., 2006). Attitudes
toward parenting and future hopes, aspirations, and
plans in this cohort also deserve additional explora-
tion, especially given the fact that many of these young
women grew up in broken households and were not
exposed to appropriate parental role modeling.
This study raises important questions and empha-
sizes the urgent need for data collection and better
understanding of the psychobiologic dynamics in the
PAH population, so that creative approaches and
evidence-based guidelines for the management of
pregnancies and postpartum care can be drafted. The
adverse health outcomes observed in the PAH group
occurred despite the presence of a healthcare system
providing intensive and integrated multidisciplinary
medical and psychosocial care that is uniquely sensi-
tive to their special needs during pregnancy and the
postnatal periods. Multicenter studies addressing
pregnancy management, monitoring, and long- term
pediatric follow-up will help to identify intervention
strategies targeted at PAH mothers and their children.
In addition to guiding management in developed
nations, these interventions may be adapted and
implemented in resource-poor settings where a bur-
geoningcohortofyoungwomenwithPAHwithaccess
to cART will be entering their childbearing years over
the next few decades.
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